Octreotide and gastrointestinal fistulae.
The place of somatostatin and its analogues in the management of gastrointestinal fistulae is reviewed, drawing attention to the difficulty of assessing treatments that influence spontaneous closure. Sixteen patients with gastric, small bowel, and pancreatic fistulae were randomized to receive octreotide injections (100 micrograms t.i.d.) or placebo for 12 days. Spontaneous fistula closure occurred in 7 at a mean of 37 days after entering the trial. A second study is underway with greater patient numbers recruited from peripheral hospitals and with an increased period of octreotide medication (21 days).
Scott
N A
NA
University Department of Surgery, Hope Hospital, Salford, UK.
Finnegan
S
S
Irving
M H
MH
D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D005260:Female; D005747:Gastric Fistula / Q000188:drug therapy*; D006801:Humans; D007412:Intestinal Fistula / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D015282:Octreotide